ReviewBMJ global health2023
Improving access to medicines and beyond: the national volume-based procurement policy in China.
Review in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Decentralisation of the Healthcare Systems and the Functioning of Public Health Programmes in Single-Party States: A Systematic Review.The International journal of health planning and management · 2026Pooled it
- Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.Human vaccines & immunotherapeutics · 2026Article
- Impact of national volume-based procurement on physicians' antimicrobial prescribing behaviours: an interrupted time series analysis of 1200 prescriptions in a tertiary hospital.Annals of medicine · 2026Article
- Observational
- Article
- [Long-term evolution, effect analysis and future trend of the burden of gastritis and duodenitis in China: An analysis based on GBD 2023].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Comparative Cost-Utility and Clinical Efficacy of 5-HT3 Receptor Antagonists in Sufentanil-Based PCIA: A Propensity Score-Matched Analysis.Pain and therapy · 2026Article
- Article
- Drug price trends, regional disparities, and supply shortages under China's National Volume-Based Procurement: a nationwide analysis (2018-2024).BMC health services research · 2026Article
- Practice model of unit-based clinical pharmacists' individualized daily antimicrobial use density monitoring report on antimicrobial stewardship in intensive care unit of a tertiary hospital in Guangxi, China: an interrupted time series analysis.Antimicrobial resistance and infection control · 2026Article
- Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China.Infectious medicine · 2026Article
- Workload and personnel allocation in pharmacy departments of public hospitals in China: a current state study.Scientific reports · 2026Article
- Diagnosis-Related group payment and its impact on hospitalization costs and patient financial protection for neurointerventional stroke care in a Chinese tertiary hospital: a retrospective analysis.Cost effectiveness and resource allocation : C/E · 2026Article
- Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs.BMC health services research · 2026Article
- Has volume-based procurement reduced household catastrophic health expenditure in rural patients with chronic disease?-Evidence from CHARLS 2018 and 2020 in China.Health economics review · 2026Article
- Dynamic evaluation and continuous improvement model of pharmaceutical administration based on DPSIR-TOPSIS.BMC health services research · 2026Article
- Real-World Evidence on Hospitalization Costs of Pediatric Neoplasm Patients in China: Patterns, Trends, and Associated Factors From a Retrospective Cohort Study.Cancer medicine · 2026Article
- Article
- The impact of China's National Drug Centralized Procurement Policy on pharmaceutical firm innovation: evidence from a staggered difference-in-differences analysis.Journal of pharmaceutical policy and practice · 2026Article
- Policy integration fluctuations in China's rural toilet revolution: typology and strategies for public health governance.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2019, the Chinese central government has taken significant steps to centralize national purchasing power and has implemented a pooled procurement system. In this paper, we provide an in-depth analysis of China's National Volume-Based Procurement (NVBP) policy, which represents a unique approach to pooled procurement within the pharmaceutical sector. The primary objectives of the NVBP are to reduce drug prices, enhance access to affordable medications, and improve the overall functioning of the pharmaceutical industry in China. Our analysis delves into the key features of the NVBP, including its centralized procurement system, volume-based procurement approach, and the guaranteed procurement volumes allocated to winning bidders. We also address the challenges and implications associated with the NVBP, such as its impact on the pharmaceutical industry, the sustainability of price reductions, and the importance of striking a balance between price reduction and industry sustainability. Through a comparative analysis, we shed light on the distinct characteristics of China's approach to pooled procurement and its potential ramifications for healthcare policies and practices. By examining the NVBP within the broader context of China's evolving healthcare landscape, we aim to contribute to a deeper understanding of the implications and effectiveness of this unique policy initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.